Filing Details
- Accession Number:
- 0001209191-22-048790
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-06 17:03:50
- Reporting Period:
- 2022-09-01
- Accepted Time:
- 2022-09-06 17:03:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1400971 | L Bradley Campbell | C/O Amicus Therapeutics, Inc. 3675 Market Street Philadelphia PA 19104 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-09-01 | 5,470 | $3.53 | 695,088 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-09-01 | 5,470 | $11.29 | 689,618 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Disposition | 2022-09-01 | 5,470 | $0.00 | 5,470 | $3.53 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 16,425 | 2023-01-28 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.99 to $11.57 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of the options were fully vested and exercisable as of the transaction date.
Billionaire Hedge Funds
